By Dr. Ajit Jha, MBBS, MD Medicine — Lifetime Member, Indian Medical Association. About the Author | Editorial Policy
Most patients with kidney disease are told to be cautious with new medications. Yet one of the largest kidney trials ever conducted has just delivered a striking verdict on semaglutide — the drug sold as Ozempic and Wegovy — and it is not what most people expected.
📋 Key Takeaways
- The FLOW trial showed semaglutide reduced the risk of serious kidney events by 24% in people with type 2 diabetes and chronic kidney disease
- Semaglutide is generally safe for people with mild to moderate kidney disease (CKD stages 1–3)
- Severe kidney disease (CKD stage 4–5) or dialysis requires specialist guidance before use
- Nausea and vomiting from Ozempic can cause dehydration — a real concern for kidney patients
- Dose adjustments are not required for kidney impairment, but monitoring is essential
Why Kidney Patients Are Watching Ozempic Closely
Chronic kidney disease (CKD) affects an estimated 850 million people worldwide, and India carries one of the highest burdens — with roughly 17% of adults showing signs of kidney dysfunction. For the millions of Indians with both type 2 diabetes and CKD, choosing safe medications is complicated. Many drugs — including metformin at higher doses — are restricted or contraindicated once kidney function declines.
Semaglutide, however, is in a different category. Unlike metformin, which is excreted by the kidneys and can accumulate dangerously when they fail, semaglutide is broken down by the body’s own enzymes — not filtered through the kidneys. This pharmacological difference has major implications for safety.
The FLOW Trial: The Biggest Kidney Evidence Yet
The landmark evidence comes from the FLOW trial (Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes), published in the New England Journal of Medicine in 2024. This was the first dedicated trial of a GLP-1 receptor agonist specifically in people with CKD.
The trial enrolled 3,533 patients with type 2 diabetes and chronic kidney disease (eGFR 50–75 mL/min/1.73m², meaning moderate impairment). Half received weekly semaglutide injections (1 mg), and half received a placebo, both on top of standard care. The trial was stopped early — after a median of 3.4 years — because the results were so strongly in favour of semaglutide.
What the FLOW Trial Found
| Outcome | Semaglutide | Placebo | Risk Reduction |
|---|---|---|---|
| Kidney failure or 50% decline in eGFR | 11.4% | 14.5% | 24% lower risk |
| Cardiovascular death or kidney failure | 19.5% | 24.9% | 23% lower risk |
| Rate of eGFR decline per year | 1.16 mL/min slower | — | Significantly preserved |
The trial was powerful enough that the FDA used it to update semaglutide’s labelling, explicitly listing kidney protection as a benefit in patients with type 2 diabetes and CKD.
How Does Semaglutide Protect the Kidneys?
The mechanisms are not fully understood, but researchers have identified several pathways:
- Blood pressure reduction — Semaglutide consistently lowers systolic blood pressure by 3–5 mmHg. Sustained high blood pressure is one of the leading drivers of kidney damage.
- Blood sugar control — Poor glycaemic control accelerates diabetic nephropathy. Semaglutide’s powerful glucose-lowering effect directly slows this damage.
- Weight loss — Obesity independently harms the kidneys through increased glomerular pressure and hyperfiltration. Losing 10–15% of body weight relieves this mechanical stress.
- Anti-inflammatory effects — GLP-1 receptors are expressed in kidney tubular cells. Direct GLP-1 agonism appears to reduce local inflammation and oxidative stress.
- Reduced albuminuria — The FLOW trial showed a significant reduction in urine albumin-to-creatinine ratio, a key marker of kidney damage.
Who Can Safely Use Ozempic with Kidney Disease?
CKD Stages 1–3 (eGFR above 30): Generally Safe
The evidence strongly supports semaglutide use in people with mild to moderate kidney disease. No dose adjustment is needed. The FLOW trial specifically studied this group and showed clear benefit. Most nephrologists and endocrinologists now consider semaglutide a preferred agent in this population.
CKD Stage 4 (eGFR 15–29): Use With Caution
Semaglutide itself does not accumulate in kidney failure, but this stage of CKD brings other complications — more severe nausea, greater dehydration risk, and complex medication interactions. The FLOW trial had limited data for this group. Specialist input from a nephrologist is essential before starting.
CKD Stage 5 / Dialysis (eGFR below 15): Limited Data
Patients on dialysis or with eGFR below 15 were excluded from the FLOW trial. Small observational studies suggest semaglutide may still be used, but the evidence base is thin. This decision should be made by a nephrologist familiar with the individual patient’s situation.
Kidney Transplant Recipients
Very limited data. Some immunosuppressants interact with GLP-1 drugs. Transplant team involvement is mandatory before starting semaglutide.
The Dehydration Risk: The Most Important Caution
Even when semaglutide is appropriate, kidney patients face one serious practical risk: dehydration from nausea and vomiting.
Up to 20% of people starting semaglutide experience significant nausea, especially in the first 4–8 weeks as the dose is escalated. For a healthy person, this is uncomfortable but manageable. For someone with CKD, dehydration causes acute kidney injury — a sudden, potentially irreversible drop in kidney function that can push a patient toward dialysis faster than years of chronic disease would.
This does not mean CKD patients cannot use semaglutide — it means they need specific monitoring:
- Kidney function tests (serum creatinine, eGFR) 4–6 weeks after starting
- Electrolyte checks if nausea is severe
- Clear instructions to drink adequately and to report persistent vomiting immediately
- Slower dose escalation if tolerability is poor
Dr. Ajit Jha's Clinical Perspective
“The FLOW trial genuinely changed how I counsel patients with diabetic kidney disease. Before this data, semaglutide was something we considered for sugar control and weight — the kidney protection was a bonus we hoped for. Now it is a primary reason to prescribe it in the right patient. That said, the dehydration risk is real and often underestimated. I ask every CKD patient starting semaglutide to check in at 4 weeks specifically for kidney function, regardless of how they feel.”
— Dr. Ajit Jha, MBBS, MD Medicine, IMA Lifetime Member
Semaglutide vs Other Diabetes Drugs in CKD
It is worth comparing semaglutide to the alternatives commonly used in India for diabetic CKD:
- Metformin — Contraindicated when eGFR falls below 30. Risk of lactic acidosis. Cannot be used in advanced CKD.
- Sulfonylureas — Risk of severe hypoglycaemia worsens with CKD. Glipizide is safest; glibenclamide should be avoided.
- SGLT2 inhibitors (dapagliflozin, empagliflozin) — Also kidney-protective (DAPA-CKD, EMPA-KIDNEY trials), but lose glucose-lowering efficacy as eGFR falls. Best used alongside semaglutide in early CKD.
- DPP-4 inhibitors (sitagliptin) — Safe in CKD but require dose reduction and offer no kidney protection.
- Insulin — Safe in all CKD stages but requires dose adjustment as kidneys clear less insulin in advanced disease.
Semaglutide + SGLT2 inhibitor is emerging as the preferred combination in diabetic CKD stages 1–3, supported by overlapping and additive evidence from FLOW, DAPA-CKD, and EMPA-KIDNEY trials.
What This Means for Indian Patients
India has a uniquely high burden of diabetic kidney disease. Type 2 diabetes is present in roughly 101 million Indians, and a significant proportion already have some degree of kidney impairment at diagnosis — often because diabetes goes undetected for years. Cost remains a significant barrier: semaglutide in India is priced at ₹7,000–12,000 per month depending on dose and formulation, which is prohibitive for most.
However, for Indians with diabetes, CKD, and the financial means to access it, semaglutide is no longer just a weight loss drug or a sugar pill. It is now a kidney medicine with a class-leading evidence base. The conversation with your doctor should include this data — not just HbA1c targets.
Frequently Asked Questions
Does Ozempic damage the kidneys?
No — the evidence suggests the opposite. The FLOW trial showed semaglutide reduced the risk of serious kidney events by 24% in people with diabetic chronic kidney disease. Ozempic does not accumulate in the kidneys and does not directly damage kidney tissue.
Can I take Ozempic if I am on dialysis?
There is very limited safety data for patients on dialysis. Semaglutide itself is not removed by dialysis, so blood levels may behave differently. This decision must involve your nephrologist and dialysis team.
Do I need to adjust my Ozempic dose if I have kidney disease?
No dose adjustment is required for kidney impairment with semaglutide, which is one of its advantages over many other diabetes medications. However, closer monitoring of kidney function is recommended.
What symptoms should kidney patients watch for on Ozempic?
Watch for severe nausea, vomiting, or diarrhoea that prevents adequate fluid intake — this can cause dehydration and acute kidney injury. Contact your doctor immediately if you cannot keep fluids down for more than 24 hours.
Is Ozempic available in India for kidney disease patients?
Semaglutide (Ozempic) is CDSCO-approved in India. It is not specifically approved for kidney disease indication in India yet, but physicians can prescribe it for diabetic patients with CKD based on international evidence. Cost and availability vary by city.
📖 Related Articles